Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
SIRT1 CRISPR Activation Plasmid (h): sc-400085-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- SIRT1 CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- SIRT1 CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by SIRT1 CRISPR Activation Plasmid (h) and SIRT1 CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the SIRT1 transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: SIRT1 Antibody (B-10): sc-74504
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
SIRT1 CRISPR Activation Plasmid (h) | sc-400085-ACT | 20 µg | $397.00 | |||
SIRT1 CRISPR Activation Plasmid (h2) | sc-400085-ACT-2 | 20 µg | $397.00 |
Human SIRT1 encodes an NAD+-dependent class III histone deacetylase that modulates chromatin accessibility and transcriptional programs by deacetylating histone and non-histone substrates, including p53, FOXO factors, NF-κB, and PGC-1α. Through these targets, SIRT1 integrates nutrient sensing with stress responses, mitochondrial biogenesis, autophagy, and DNA damage repair pathways. SIRT1 activity influences metabolic homeostasis, inflammation, and cellular senescence, linking its dysregulation to cardiometabolic disease biology, neurodegeneration-associated mechanisms, and tumor-relevant transcriptional reprogramming. As a central epigenetic and signaling node, SIRT1 is frequently investigated in models of oxidative stress, aging-related phenotypes, and immune activation.
SIRT1 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous SIRT1 expression without altering the underlying DNA sequence.
SIRT1 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the SIRT1 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the SIRT1 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous SIRT1 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native SIRT1 locus and enabling the study of SIRT1-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of SIRT1 pathway restoration in tumor cells with silenced or reduced SIRT1 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.